Massive german study to track how blood cancer patients really fare
NCT ID NCT06043011
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study is a large registry that will follow nearly 3,000 people with blood cancers like chronic lymphocytic leukemia and several types of lymphoma. Researchers will collect information on treatments, how the disease progresses, and patients' quality of life over time. The goal is to understand what happens in everyday medical practice, not to test a new drug or therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,950 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2023
- Expected to finish
-
Dec 2033
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients with hematologic malignancies requiring systemic treatment
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Confirmed diagnosis of the respective NHL * If patient is alive: signed written informed consent * For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment. * For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment. Exclusion Criteria: * No systemic therapy for respective lymphoid malignancy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia (CLL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Praxis für Interdisziplinäre Hämatologie und Onkologie
RECRUITINGFreiburg im Breisgau, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a bispecific antibody wipe out residual leukemia cells in High-Risk CLL?
- Proton beams vs. X-Rays: can a pricier radiation spare hearts and prevent second cancers?
- Real-World data may reveal how acalabrutinib performs in chinese blood cancer patients
- Can a drug combo shrink Hard-to-Treat lymphoma tumors?
- Can 'Memory-Enhanced' immune cells outsmart lymphoma?
- Can a Two-Drug combo keep CLL at bay for years? a 10-Year watch begins